Total Voting Rights (6605A)
April 02 2012 - 12:21PM
UK Regulatory
TIDMHIK
RNS Number : 6605A
Hikma Pharmaceuticals Plc
02 April 2012
Hikma Pharmaceuticals PLC - Voting Rights and Capital
LONDON, 2 April 2012 Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) notifies the market that as at 31 March 2012 its
capital consists of 196,806,607 ordinary shares with voting rights.
There are no shares held in treasury.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest
in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and
Transparency Rules.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Deputy Company Secretary +44 20 7399 2760
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non--branded generic
and in--licensed products. Hikma's operations are conducted through
three businesses: "Branded", "Injectables" and "Generics" based
principally in the Middle East and North Africa ("MENA") region,
where it is a market leader, the United States and Europe. In 2011,
Hikma achieved revenue of $918.0 million and profit attributable to
shareholders of $80.1 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVREAKLAEAFAEFF
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024